Stock Scorecard

Stock Summary for Gain Therapeutics Inc (GANX) - $1.82 as of 11/20/2024 4:05:54 PM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for GANX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for GANX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for GANX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for GANX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for GANX (15 out of 90)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0

Latest News for for GANX

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Gain Therapeutics ( NASDAQ:GANX ) 10/15/2024 11:00:00 AM
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 - Gain Therapeutics ( NASDAQ:GANX ) 10/7/2024 11:00:00 AM
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 10/7/2024 11:00:00 AM
Gain Therapeutics to Participate at Upcoming Investor Conferences 10/3/2024 11:00:00 AM
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers - Gain Therapeutics ( NASDAQ:GANX ) 9/30/2024 11:00:00 AM
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers 9/30/2024 11:00:00 AM
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease 9/26/2024 11:00:00 AM
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024 9/19/2024 11:00:00 AM
Why Is Gain Therapeutics Stock Falling On Thursday? - Gain Therapeutics ( NASDAQ:GANX ) 8/29/2024 4:05:00 PM
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease 8/29/2024 11:30:00 AM

Financial Details for GANX

Company Overview
Ticker GANX
Company Name Gain Therapeutics Inc
Country USA
Description Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. The company is headquartered in Bethesda, Maryland.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History
Last Day Price 1.82
Price 4 Years Ago 0.00
Last Day Price Updated 11/20/2024 4:05:54 PM EST
Last Day Volume 141,675
Average Daily Volume 353,938
52-Week High 5.33
52-Week Low 0.89
Last Price to 52 Week Low 104.49%

Valuation Measures
Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -2.44
Free Cash Flow Ratio 4.04
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 2.99
Total Cash Per Share 0.45
Book Value Per Share Most Recent Quarter 0.78
Price to Book Ratio 5.12
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 925.92
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 2

Share Statistics
Total Shares Outstanding 26,525,100
Market Capitalization 48,275,682
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -26.59%
Reported EPS 12 Trailing Months -1.07
Reported EPS Past Year -0.81
Reported EPS Prior Year -1.78
Net Income Twelve Trailing Months -21,366,933
Net Income Past Year -22,267,520
Net Income Prior Year -17,590,738
Quarterly Revenue Growth YOY -100.00%
5-Year Revenue Growth -42.17%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet
Total Cash Most Recent Quarter 12,049,522
Total Cash Past Year 16,800,000
Total Cash Prior Year 20,138,565
Net Cash Position Most Recent Quarter 11,555,112
Net Cash Position Past Year 16,232,150
Long Term Debt Past Year 567,850
Long Term Debt Prior Year 603,393
Total Debt Most Recent Quarter 494,410
Equity to Debt Ratio Past Year 0.96
Equity to Debt Ratio Most Recent Quarter 0.95
Total Stockholder Equity Past Year 12,578,224
Total Stockholder Equity Prior Year 18,879,514
Total Stockholder Equity Most Recent Quarter 8,909,382

Free Cash Flow
Free Cash Flow Twelve Trailing Months -21,101,137
Free Cash Flow Per Share Twelve Trailing Months -0.80
Free Cash Flow Past Year -18,881,231
Free Cash Flow Prior Year -14,811,092

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.07
MACD Signal 0.03
20-Day Bollinger Lower Band 0.57
20-Day Bollinger Middle Band 1.63
20-Day Bollinger Upper Band 2.69
Beta 0.34
RSI 41.96
50-Day SMA 2.60
150-Day SMA 3.41
200-Day SMA 0.00

System
Modified 11/21/2024 1:34:16 AM EST